CONMED Corp.
https://www.conmed.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CONMED Corp.
Amgen And Synaffix Alliance Could Be Biggest Preclinical ADC Licensing Deal Yet
Amgen has signed two big early-stage deals in a matter of days, signalling that antibody-drug conjugates are a priority target in oncology for the firm.
Dealmaking Quarterly Statistics, Q3 2022
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
EMA OKs First Drug To Prevent RSV Infection In Babies
A new medicine to protect newborns and infants from RSV infection and a new treatment for DLBCL are among a dozen drugs that have been recommended for pan-EU approval.
Nicotine Gummies Sold For Smoking Cessation Doused Under US FDA Tobacco Regulations
FDA says warning to VPR Brands could be its first move to reign in sales of nicotine gummies. Statements on brand’s site could indicate sales of nicotine gummies for smoking cessation are on the rise even though the claim isn’t approved.
Company Information
- Industry
-
Medical Devices
- Monitoring Equipment & Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Biorez, Inc.
- Buffalo Filter
- Concept, Inc.
- In2Bones Global
- SurgiQuest, Inc.
- Viking Systems
- Linvatec Corporation
- Bionx Implants Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice